[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:solid-neoplasm:braf-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Solid Neoplasm","BRAF Gene",15,[8,16,23,30,36,42,48,54,60,66,72,78,84,90,95],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04775485","A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors",[12],"Phase 2","RECRUITING","2026-08-26T02:18:45.196599Z","2026-05-05T02:43:29.733815Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07224425","A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps",[20],"Phase 1","2026-08-26T02:16:33.772093Z","2026-05-05T02:43:27.289591Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06060613","Safety and Efficacy of OBX-115 in Advanced Solid Tumors",[27],"Phase 1\u002FPhase 2","2026-08-26T02:15:38.131683Z","2026-07-05T05:32:16.743163Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT04752826","BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)",[27],"2026-08-26T02:18:42.501841Z","2026-05-05T02:43:28.727191Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06326411","A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors",[20],"2026-08-26T02:18:13.438956Z","2026-05-05T02:43:27.481677Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06249048","Phase 1\u002F2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab",[27],"2026-08-26T02:16:38.897933Z","2026-05-05T02:43:26.920220Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT05503797","A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations",[12],"2026-08-26T02:19:21.761002Z","2026-07-30T01:46:14.464355Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05512208","A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib",[12],"2026-08-26T02:15:27.567165Z","2026-05-05T02:43:29.586102Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT05101070","S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors",[27],"2026-08-26T02:17:47.813245Z","2026-05-05T02:43:28.621667Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT05076760","MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors",[20],"2026-08-26T02:19:07.104270Z","2026-05-05T02:43:28.200826Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT05859074","A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer",[20],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:27.807952Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT05538130","A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors",[20],"2026-08-26T02:18:51.009190Z","2026-05-05T02:43:27.578185Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT05269381","Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors",[27],"2026-08-26T02:19:10.436356Z","2026-04-29T02:57:57.121665Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":64,"content_modified":94},"NCT05111561","Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced\u002FMetastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer",[20],"2026-07-24T01:27:14.906567Z",{"nct_id":96,"title":97,"phases":98,"status":99,"updated_at":100,"content_modified":101},"NCT04291105","Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:31:37.197247Z","2026-05-05T02:43:28.820519Z"]